Skip to main content
FENNEC PHARMACEUTICALS INC. logo

FENNEC PHARMACEUTICALS INC. — Investor Relations & Filings

Ticker · FENC ISIN · CA31447P1009 LEI · 5299003IE70ITO2CBM73 US Manufacturing
Open in API
Filings indexed 762 across all filing types
Latest filing 2026-05-22 Regulatory Filings
Country CA Canada
Listing US FENC

About FENNEC PHARMACEUTICALS INC.

https://fennecpharma.com/

Fennec Pharmaceuticals Inc. is a commercial-stage biopharmaceutical company focused on the development and commercialization of its proprietary product, PEDMARK®. PEDMARK is a unique formulation of sodium thiosulfate designed to reduce the risk of ototoxicity (permanent hearing loss) associated with cisplatin chemotherapy. The product is specifically indicated for pediatric patients with localized, non-metastatic solid tumors. The company's core mission is to address this significant unmet medical need in pediatric oncology, preventing lifelong hearing loss in children undergoing cancer treatment.

Recent filings

Filing Released Lang Actions
8-K
Regulatory Filings
2026-05-22 English
8-K
Regulatory Filings
2026-05-18 English
10-Q
Interim / Quarterly Report Q1 2026
2026-05-14 English
8-K - FENNEC PHARMACEUTICALS INC. (0001211583) (Filer)
Board/Management Information Classification · 100% confidence The document is a Form 8-K filed with the SEC, dated April 27, 2026, by Fennec Pharmaceuticals Inc. The key content is the announcement of a director's retirement and the reduction in the size of the Board of Directors. There is no financial data, earnings information, or report publication mentioned. The primary subject is a change in the company's board composition, which fits the category of Board/Management Information (MANG). The document length is 3437 characters, which is relatively short but contains substantive information about management changes, not just an announcement of a report. Therefore, the correct classification is MANG with high confidence.
2026-04-28 English
8-K - FENNEC PHARMACEUTICALS INC. (0001211583) (Filer)
Regulatory Filings Classification · 95% confidence The document is a Form 8-K filed with the SEC, which is a Current Report used to announce unscheduled material events or corporate changes. The text indicates it announces the initiation of a clinical study and includes a press release as an exhibit. There are no financial statements or detailed financial data presented. The document length is 3610 characters, which is relatively short and mainly serves as an announcement rather than a full report. It does not fit into categories like Annual Report, Earnings Release, or Interim Report. It is not a certification or officer attestation. The content is an event announcement and press release filing, which is best classified under Regulatory Filings (RNS) as a general regulatory announcement that does not fit other specific categories.
2026-04-07 English
10-K - FENNEC PHARMACEUTICALS INC. (0001211583) (Filer)
Annual Report FY 2025
2026-03-27 English

Browse filings by year

25 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.